The National Health Insurance Service is planning to improve the Risk Sharing Agreement (RSA) Scheme and is also discussing measures to improve the Price-Volume Agreement (PVA) system to reflect rewards for the innovative value of new drugs.

The Department of Drug Management at NHIS said so at a press conference with correspondents on the 29th.

Hae Min Jung, Director of the Department of Drug Management at NHIS, said “We are reflecting the results of the research service that was conducted to improve the RSA system, and advancing the system to achieve both the rapid listing of high-priced drugs and financial soundness of NHI finances. The demand for expansion of RSA subjects has been i